Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Asian Market Insights: Shenzhen New Industries Biomedical Engineering And 2 Other Stocks Estimated Below Fair Value

In This Article:

Amidst global economic uncertainties and fluctuating indices, the Asian markets have shown resilience, with China's stimulus hopes driving a recent uptick in mainland stock exchanges. As investors navigate these complex conditions, identifying undervalued stocks becomes crucial for those looking to capitalize on potential market inefficiencies.

Top 10 Undervalued Stocks Based On Cash Flows In Asia

Name

Current Price

Fair Value (Est)

Discount (Est)

Guizhou Space Appliance (SZSE:002025)

CN¥58.35

CN¥115.75

49.6%

APAC Realty (SGX:CLN)

SGD0.43

SGD0.85

49.5%

Takara Bio (TSE:4974)

¥853.00

¥1686.88

49.4%

Food & Life Companies (TSE:3563)

¥4349.00

¥8695.25

50%

Nan Ya Printed Circuit Board (TWSE:8046)

NT$131.50

NT$262.21

49.8%

Nanofilm Technologies International (SGX:MZH)

SGD0.67

SGD1.33

49.6%

Intellian Technologies (KOSDAQ:A189300)

₩38200.00

₩75949.64

49.7%

Jiangsu Chuanzhiboke Education Technology (SZSE:003032)

CN¥8.53

CN¥16.91

49.6%

Shenzhen Anche Technologies (SZSE:300572)

CN¥18.60

CN¥37.18

50%

Doosan Fuel Cell (KOSE:A336260)

₩15880.00

₩31498.51

49.6%

Click here to see the full list of 275 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

We're going to check out a few of the best picks from our screener tool.

Shenzhen New Industries Biomedical Engineering

Overview: Shenzhen New Industries Biomedical Engineering Co., Ltd. focuses on the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals both in China and internationally, with a market cap of CN¥47.09 billion.

Operations: The company generates revenue primarily from its in vitro diagnostic segment, amounting to CN¥4.44 billion.

Estimated Discount To Fair Value: 16.1%

Shenzhen New Industries Biomedical Engineering is trading at CN¥59.93, approximately 16.1% below its estimated fair value of CN¥71.44, indicating it may be undervalued based on cash flows. Despite earnings forecasted to grow slower than the Chinese market at 21.1% annually, revenue is expected to rise faster than the market at 20.7% per year. However, its unstable dividend track record may concern income-focused investors despite a high future return on equity of 23.6%.

SZSE:300832 Discounted Cash Flow as at Mar 2025
SZSE:300832 Discounted Cash Flow as at Mar 2025

Food & Life Companies

Overview: Food & Life Companies Ltd. operates a chain of sushi restaurants with a market cap of ¥491.99 billion.